Results 11 to 20 of about 32,890 (266)

Ustekinumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Patients with ulcerative colitis (UC) may be concerned about medication safety during preconception, pregnancy, and lactation, and they should be closely followed up to ensure that UC activity is controlled during the perinatal period ...
Jumpei Saito, Kayoko Kaneko, Hiroyo Kawasaki, Takeshi Hayakawa, Naho Yakuwa, Tomo Suzuki, Haruhiko Sago, Akimasa Yamatani, Atsuko Murashima   +8 more
doaj   +1 more source

Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy

AboutOpen, 2023
Background: The aim of this economic evaluation was to compare the cost per responder between vedolizumab and ustekinumab in patients with Crohn’s disease (CD) after failure of tumor necrosis factor-α inhibitors in Italy.
Roberto Ravasio, Raffaella Viti, Antonio Saverio Roscini   +2 more
doaj   +1 more source

The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab. [PDF]

PLoS ONE, 2015
Immunogenicity due to antidrug antibodies (ADA) to tumor necrosis factor (TNF)-α antagonists is known to decrease treatment response. However, few studies have investigated ADA in ustekinumab, an interleukin-12 and -23 antagonist, in a clinical setting ...
Hsien-Yi Chiu, Thomas Waitao Chu, Yu-Pin Cheng, Tsen-Fang Tsai   +3 more
doaj   +1 more source

Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report

Case Reports in Dermatology, 2021
Ustekinumab is a fully human monoclonal antibody targeting the pro-inflammatory cytokines interleukin (IL)-12 and IL-23 approved for the treatment of psoriasis and psoriatic arthritis.
Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi   +3 more
doaj   +1 more source

Body mass index, disease duration and tumor necrosis factor inhibitor history predict reduced ustekinumab response in Chinese psoriasis patients: A real-world study

Indian Journal of Dermatology, 2021
Background: Ustekinumab, as a monoclonal antibody against interleukin (IL)-12 and IL-23, gets approved in China since 2019, therefore fewstudies report the application of ustekinumab in treating Chinese psoriasis patients in the real clinical settings ...
Xue Xu, Guifang Qin, Zudong Meng, Dan Pei   +3 more
doaj   +1 more source

Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study

Therapeutic Advances in Gastroenterology, 2023
Background: Clinical trials have demonstrated the efficacy and safety of ustekinumab in Crohn’s disease (CD). However, more data are necessary on the effectiveness of ustekinumab in bio-naïve patients in real-life studies.
Valdés Delgado Teresa, Olmedo Martín Rául, Iborra Marisa, Herrera de Guisé Claudia, Fuentes-Valenzuela Esteban, Melcarne Luigi, Martín-Rodríguez Mª Mar, Kolle Casso Lilyan, De Castro Parga Luisa, Ponferrada Díaz Ángel, Vicente Lidón Raquel, Manceñido Marcos Noemí, Velayos Jiménez Benito, Lázaro Sáez Marta, López Cauce Beatriz, Mesonero Gismero Francisco, Gilabert Álvarez Pau, Argüelles-Arias Federico   +17 more
doaj   +1 more source

Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use

Frontiers in Pharmacology, 2023
Background: Ustekinumab is used off-label in pediatric Crohn’s disease refractory to anti-tumor necrosis factor. Data on optimal dosing, target trough levels, and potential benefit of therapeutic drug monitoring in children treated with ustekinumab are ...
Marleen Bouhuys, Paola Mian, Patrick F. van Rheenen   +2 more
doaj   +1 more source

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study

Therapeutic Advances in Gastroenterology, 2021
Background: Vedolizumab demonstrated different placental pharmacokinetics than other immunoglobulin G1 antibodies, leading to lower drug levels in cord blood in contrast to maternal blood at the time of delivery.
Katarina Mitrova, Barbora Pipek, Martin Bortlik, Ludek Bouchner, Jan Brezina, Tomas Douda, Tomas Drasar, Pavel Drastich, Premysl Falt, Pavel Klvana, Vaclav Leksa, Ales Novotny, Pavel Svoboda, Jan Skorpik, Jan Ulbrych, Marek Veinfurt, Blanka Zborilova, Milan Lukas, Dana Duricova   +18 more
doaj   +1 more source

High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab

Vaccines, 2020
Influenza vaccination can be less effective in patients treated with immunosuppressive therapy. However, little is known about the effects of ustekinumab; an anti-IL-12/23 agent used to treat Crohn’s disease (CD), on vaccination response.
Laura Doornekamp, Rogier L. Goetgebuer, Katharina S. Schmitz, Marco Goeijenbier, C. Janneke van der Woude, Ron Fouchier, Eric C.M. van Gorp, Annemarie C. de Vries   +7 more
doaj   +1 more source

Flare-up of pustular psoriasis after ustekinumab therapy: Case report and literature review

Dermatologica Sinica, 2018
While tumor necrosis factor-alpha (TNF-α) inhibitor has been shown to be paradoxically associated with the development of psoriasis, there are few reported cases of pustular psoriasis potentially induced by ustekinumab in the literature.
Ying-Xiu Dai, Chih-Chiang Chen
doaj   +1 more source